Status:
RECRUITING
Prospective Asian Multicenter Prostate Cancer Focal Therapy Study (ProAMFocal)
Lead Sponsor:
Singapore General Hospital
Collaborating Sponsors:
National Medical Research Council (NMRC), Singapore
Conditions:
Prostate Cancer
Eligibility:
MALE
40-85 years
Brief Summary
This is a multicenter observational study of patients undergoing focal therapy for prostate cancer in Asia
Detailed Description
Patients undergoing Focal Cryotherapy, Focal HIFU, Focal IRE, Focal Laser ablation, or other partial gland ablation modalities for prostate cancer will be recruited.
Eligibility Criteria
Inclusion
- Prostate Adenocarcinoma
- Maximum Gleason score 4+4
- Maximum cancer volume 1.5 ml (up to 2 lesions) or 3 ml (single lesion)
- Maximum Prostate Specific Antigen (PSA) level 15 ng/dl
- Maximum clinical stage T2c
- American Society of Anesthesiologist Criteria 2 or less
Exclusion
- Extra-prostatic Extension on multi parametric magnetic resonance imaging (mpMRI); capsular contact is permitted
Key Trial Info
Start Date :
May 6 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 6 2048
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06491056
Start Date
May 6 2023
End Date
May 6 2048
Last Update
July 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Singapore General Hospital
Singapore, Singapore, 169856